Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Usefulness of Rapid Desensitization Therapy for Severe Rash Caused by Molecularly Targeted Drugs Used in the Treatment of Non-small-cell Lung Cancer.

Tytuł:
Usefulness of Rapid Desensitization Therapy for Severe Rash Caused by Molecularly Targeted Drugs Used in the Treatment of Non-small-cell Lung Cancer.
Autorzy:
Nagase M; Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan.
Ohshima N; Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan.
Kawashima M; Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan.
Ohgiya M; Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan.
Ikeda M; Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan.
Morio Y; Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan.
Tamura A; Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan.
Źródło:
Internal medicine (Tokyo, Japan) [Intern Med] 2020 Dec 15; Vol. 59 (24), pp. 3201-3205. Date of Electronic Publication: 2020 Aug 12.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Tokyo, Japan : Japanese Society of Internal Medicine, [1992-
MeSH Terms:
Antineoplastic Agents*/adverse effects
Carcinoma, Non-Small-Cell Lung*/drug therapy
Exanthema*/chemically induced
Exanthema*/drug therapy
Lung Neoplasms*/drug therapy
Pharmaceutical Preparations*
Anaplastic Lymphoma Kinase ; ErbB Receptors/genetics ; Humans ; Mutation ; Neoplasm Recurrence, Local ; Protein Kinase Inhibitors/adverse effects
References:
Nat Rev Cancer. 2006 Oct;6(10):803-12. (PMID: 16990857)
Kekkaku. 2014 Nov;89(11):797-802. (PMID: 25730947)
J Thorac Oncol. 2012 Aug;7(8):1296-303. (PMID: 22610257)
Respir Med. 2019 Feb;147:44-50. (PMID: 30704698)
J Thorac Oncol. 2014 Nov;9(11):1726-8. (PMID: 25436807)
Eur J Immunol. 2011 Apr;41(4):1004-13. (PMID: 21360700)
J Allergy Clin Immunol. 2009 Mar;123(3):701-3. (PMID: 19121858)
Int J Gynecol Cancer. 2009 Oct;19(7):1284-7. (PMID: 19823066)
Jpn J Clin Oncol. 2016 Apr;46(4):291-8. (PMID: 26826719)
Contributed Indexing:
Keywords: ALK inhibitor; EGFR-TKI; NSCLC; rapid desensitization therapy
Substance Nomenclature:
0 (Antineoplastic Agents)
0 (Pharmaceutical Preparations)
0 (Protein Kinase Inhibitors)
EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
EC 2.7.10.1 (ErbB Receptors)
Entry Date(s):
Date Created: 20200814 Date Completed: 20210414 Latest Revision: 20210414
Update Code:
20240105
PubMed Central ID:
PMC7807110
DOI:
10.2169/internalmedicine.5048-20
PMID:
32788540
Czasopismo naukowe
Molecular-targeted drugs (MTDs), such as epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and anaplastic lymphoma kinase inhibitors, are used to treat non-small-cell lung cancer (NSCLC). The incidence of rash caused by EGFR-TKIs and discontinuation of MTDs because of rash are issues. Rapid desensitization therapy (RDT) was performed in five patients who developed severe rash after introduction of MTDs and was successful in four, all of whom showed no rash relapse. RDT may thus be useful for treating rash in patients receiving MTDs for NSCLC.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies